|
AU2007329592A1
|
|
Methods of imaging employing chelating agents
|
|
AU2007244705A1
|
|
Detection and imaging of target tissue
|
|
AU2007201577A1
|
|
Enhanced ultrasound detection with temperature-dependent contrast agents
|
|
US2007237721A1
|
|
Targeted MR imaging agents
|
|
AU2006320488A1
|
|
Methods to ameliorate and image angioplasty-induced vascular injury
|
|
US2007012105A1
|
|
Method and apparatus for resistive characteristic assessment
|
|
AU2005220706A1
|
|
Improved efficacy and safety of targeted particulate agents with decoy systems
|
|
AU2004293027A1
|
|
Enhanced drug delivery
|
|
WO2005027848A2
|
|
Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
|
|
WO2005037852A2
|
|
Trimerizing polypeptides and their uses
|
|
AU2004263136A1
|
|
Emulsion particles for imaging and therapy and methods of use thereof
|
|
AU2004202725A1
|
|
Site specific binding system, nuclear imaging compositions and methods
|
|
WO2004067483A2
|
|
Chelating agents with lipophilic carriers
|
|
CA2559889A1
|
|
Targeted atherosclerosis treatment
|
|
US2004203072A1
|
|
Uncoupled collagen synthesis and degradation assays
|
|
AU2003295424A1
|
|
Methods and compositions for prostate epithelial cell differentiation
|
|
US2005080370A1
|
|
Method and apparatus for determining a dorsiflexion angle
|
|
AU2003268219A1
|
|
Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
|
|
WO2004013647A1
|
|
Method and apparatus for intracorporeal medical mr imaging using self-tuned coils
|
|
EP1530729A1
|
|
Method and apparatus for intracorporeal medical mr imaging using self-tuned coils
|
